Biomarker Discovery in Parkinson's Disease:Present Challenges and Future Opportunities  

作　　者：Song Li Weidong Le 

机构地区：[1]Clinical Research Center on Neurological Diseases, The First Affiliated Hospital, Dalian Medical University,Dalian 116011, China [2]Liaoning Provincial Key Laboratory for Research on the Pathogenic Mechanisms of Neurological Diseases, The First Affiliated Hospital, Dalian Medical University,Dalian 116011, China [3]Collaborative Innovation Center for Brain Science, The First Affiliated Hospital, Dalian Medical University,Dalian 116011, China

出　　处：《Neuroscience Bulletin》2017年第5期481-482,共2页神经科学通报（英文版）

基　　金：supported by the National Natural Science Foundation of China (81430021 and 81370470)

摘　　要：Parkinson＇s disease （PD） is the second most common neurodegenerative disorder affecting more than 1% of the older population. Histopathologically, PD is characterized by a severe loss of dopaminergic neurons in the substantia nigra and cytoplasmic inclusions composed of insoluble protein aggregates （Lewy bodies）, which lead to a pro- gressive movement disorder including the classic triad of tremor, bradykinesia, and rigidity.Parkinson＇s disease （PD） is the second most common neurodegenerative disorder affecting more than 1% of the older population. Histopathologically, PD is characterized by a severe loss of dopaminergic neurons in the substantia nigra and cytoplasmic inclusions composed of insoluble protein aggregates （Lewy bodies）, which lead to a pro- gressive movement disorder including the classic triad of tremor, bradykinesia, and rigidity.

关 键 词：PD In Biomarker Discovery in Parkinson’s Disease Present Challenges and Future Opportunities 

分 类 号：R742.5[医药卫生—神经病学与精神病学]